Novo Renamed Amycretin and Is Testing It Against Wegovy. The Key Trial Runs to 2028

Share

Novo Nordisk’s experimental obesity peptide has a new name and an unusually revealing opponent. The drug previously known as amycretin is now called zenagamtide, and a Phase 3 trial named AMAZE 7 is testing it against semaglutide, the active ingredient in Novo’s own Wegovy. Not against Eli Lilly’s tirzepatide, which defeated Novo’s CagriSema in a head-to-head study earlier this year. That choice says something about the evidence Novo wants to establish before trying to reclaim ground in the obesity market.

AMAZE 7 began in September 2026 and is expected to measure weight loss through 84 weeks, with primary completion currently estimated for October 2028. Meanwhile, Novo has also launched Phase 3 testing of oral zenagamtide. The company’s third-quarter report on November 4 confirmed that the broader AMAZE program is underway.

The early human data are encouraging, including estimated weight loss of 24.3% at 36 weeks in one small injection-study cohort. But zenagamtide has not yet demonstrated long-term superiority over semaglutide or tirzepatide in a Phase 3 trial. Its most important commercial and clinical questions remain unanswered.

What Amycretin Is, and Why Zenagamtide Is Different

Zenagamtide is an engineered peptide designed to activate GLP-1 and amylin receptor pathways within a single molecule. GLP-1 is the hormone pathway targeted by semaglutide, while amylin is released alongside insulin and helps regulate food intake, fullness and gastric emptying. The drug’s published 2026 clinical papers also describe activity at calcitonin receptors, although Novo characterizes the development program primarily as a GLP-1/amylin combination.

That makes zenagamtide chemically different from CagriSema, Novo’s other major amylin-based obesity program. CagriSema combines two separate molecules, semaglutide and the long-acting amylin analog cagrilintide, in one weekly injection. Zenagamtide brings the receptor-targeting activities together in a single peptide.

The distinction may affect manufacturing, formulation and how the molecule behaves in the body. But a single molecule is not automatically more effective than two combined drugs. Only controlled comparisons can establish whether the design leads to meaningfully better weight loss, tolerability or other outcomes.

The stakes became clearer on February 23, 2026. Novo reported results from REDEFINE 4, an 84-week, open-label Phase 3 trial comparing CagriSema with tirzepatide. Under an estimand assuming participants adhered to treatment, CagriSema achieved 23.0% weight loss versus 25.5% with tirzepatide. Under the treatment-regimen estimand, which includes outcomes regardless of treatment discontinuation, weight loss was 20.2% versus 23.6%.

CagriSema failed to demonstrate non-inferiority to tirzepatide on the trial’s primary endpoint. It remained a substantial weight-loss treatment, but it had not matched its strongest competitor under the prespecified statistical test.

Zenagamtide gives Novo another opportunity to test whether targeting GLP-1 and amylin together can produce a more competitive medicine.

What the Amycretin Evidence Actually Shows

The strongest early obesity data come from a randomized Phase 1b/2a study published in The Lancet in 2025. Researchers tested weekly subcutaneous amycretin injections in adults with overweight or obesity without diabetes. The study enrolled 125 participants, with 101 assigned to active treatment and 24 to placebo across several parts of the trial.

The results depended on dose and treatment duration. In a 36-week group escalated to 60 mg, estimated mean weight loss reached 24.3%, compared with 1.1% on placebo. Another 36-week group, using a 20 mg maintenance dose, lost 22.0% of body weight, while its small placebo comparison group had an estimated weight increase of 1.9%.

The lower-dose groups also lost weight, although they were followed for shorter periods. Estimated weight loss was 16.2% at 28 weeks with a 5 mg maintenance dose and 9.7% at 20 weeks with 1.25 mg.

These numbers cannot be treated as results from one large, uniform 36-week study. The dose groups had different schedules, relatively few participants and different placebo comparisons. The authors also reported a substantial number of withdrawals, many for reasons unrelated to treatment-emergent adverse events.

Gastrointestinal symptoms were common. Novo’s detailed presentation reported gastrointestinal adverse events in 94% of participants in the 5 mg and 20 mg groups, compared with 63% in the 1.25 mg group. Most treatment-emergent adverse events reported in the published study were mild to moderate, but the frequency is an important warning against assuming greater weight loss will come without a tolerability cost.

The investigators also reported that weight loss had not clearly plateaued in the higher-dose groups by the end of treatment. That suggests the possibility of further reductions over longer periods. It does not establish what would happen after 68, 84 or 104 weeks.

Twenty-four percent weight loss in an early study is a reason to run Phase 3. It is not a Phase 3 result.

A Larger Trial in Type 2 Diabetes

Zenagamtide’s evidence base expanded in June 2026, when Novo presented results from a 36-week Phase 2 dose-ranging trial in adults with type 2 diabetes. The findings were subsequently published in The Lancet.

The study randomized 262 adults whose blood glucose remained inadequately controlled despite metformin, with or without an SGLT2 inhibitor. Participants received one of six weekly injected doses, ranging from 0.4 mg to 40 mg, or placebo.

At the highest dose, 40 mg, estimated average HbA1c fell by 1.71 percentage points, compared with 0.14 percentage points on placebo. Average body weight fell by 14.6%, compared with 2.1% on placebo. The primary endpoint was blood-sugar control, with weight loss assessed as a secondary outcome.

These results are not directly comparable with the 24.3% weight reduction in the earlier obesity trial. The participants had different metabolic conditions, the studies used different dose regimens and the higher-dose diabetes groups spent only a limited period at their maintenance doses.

Gastrointestinal side effects again predominated. The investigators described the overall tolerability profile as consistent with other incretin- and amylin-based therapies, while emphasizing the need for larger studies.

The combined evidence supports further development. It has not established whether zenagamtide offers superior long-term efficacy or better tolerability than existing treatments.

AMAZE 7: An 84-Week Test Against Semaglutide

The AMAZE 7 registry entry, NCT07668414, states that the Phase 3 trial began on September 22, 2026. Novo plans to enroll approximately 650 adults with overweight or obesity. Participants will receive once-weekly subcutaneous zenagamtide or one of two semaglutide comparator regimens, with matched placebo injections used to maintain blinding.

All groups also receive dietary and physical-activity guidance. The principal outcome is the percentage change in body weight between baseline and week 84.

The registry currently lists October 10, 2028, as the estimated primary completion date. That is when the main trial measurements are expected to be complete, not a guaranteed date for a press release or publication.

Semaglutide is a scientifically credible comparator because it is an established GLP-1 receptor agonist with extensive clinical evidence. A positive result would help test whether the additional receptor activity designed into zenagamtide translates into better outcomes than semaglutide treatment alone.

It would not, however, directly establish superiority over tirzepatide. That remains a separate question.

Why Novo Chose Semaglutide Rather Than Tirzepatide

The comparator decision has an obvious scientific logic. Semaglutide offers an established benchmark for the GLP-1 component of zenagamtide’s activity. Testing the two head to head provides a more direct way to evaluate the clinical value of the newer molecule.

It also has a competitive limitation. Tirzepatide is already a major alternative in obesity treatment, and Novo’s earlier CagriSema head-to-head trial showed how difficult that benchmark can be. Even if zenagamtide demonstrates superiority over semaglutide, physicians and investors will still want to know how it performs against Lilly’s dual GIP/GLP-1 agonist.

The selection of an internal comparator does not prove Novo is avoiding tirzepatide. Trial designs involve scientific, regulatory and commercial considerations, and the broader zenagamtide program includes multiple studies. But AMAZE 7 alone will not settle the direct Lilly comparison.

Novo is also testing zenagamtide against semaglutide in AMAZE 8, a separate Phase 3 trial involving people with type 2 diabetes and excess body weight. Together, these comparisons could help establish the drug’s clinical position across related but distinct patient groups.

The Oral Version Has Already Reached Phase 3

The injectable program is only part of Novo’s strategy. The company is also developing oral zenagamtide, an ambitious formulation because peptide medicines are vulnerable to breakdown in the digestive tract and can be difficult to absorb.

The oral formulation is not beginning Phase 3 without human data. A separate 36-week Phase 2 study, published in The Lancet in August 2026, randomized 186 adults with type 2 diabetes to once-daily oral zenagamtide or placebo.

Participants received maintenance doses of 6 mg, 25 mg or 50 mg. Estimated mean HbA1c reductions reached 1.4 percentage points at the highest dose, with statistically significant differences from placebo across all three dose groups. Weight loss was also observed, particularly at the two higher doses. Gastrointestinal symptoms were again the most common adverse events.

The larger oral obesity trial, AMAZE 9, began on August 31, 2026, according to Novo’s public trial information. It plans to enroll approximately 950 adults and compare daily zenagamtide tablets with placebo. The listed study completion date is August 2028, although schedules can change.

Novo highlighted the start of AMAZE 9 in its November 4 third-quarter update. A successful oral GLP-1/amylin peptide could widen the company’s options in a market increasingly interested in treatments beyond weekly injections.

But convenience is not the same as proven effectiveness. The oral formulation still needs larger, longer trials to establish its benefit-risk profile in people with obesity.

The Amylin Race Around Zenagamtide

Novo is not alone in pursuing the amylin pathway. Eli Lilly is developing the investigational amylin agonist eloralintide, which Grey Pepper has covered previously. Zealand Pharma and Roche are also advancing petrelintide, including the ZUPREME Phase 2 program.

The common idea is that amylin activity may provide additional appetite and weight-control effects when used alongside GLP-1 signaling. Companies are testing different ways of delivering that biology, including separate peptides, unimolecular agonists and longer-acting formulations.

Several questions remain unresolved. One is whether additional amylin activity produces greater weight loss without an unacceptable increase in nausea and vomiting. Another is whether these treatments meaningfully change body composition, including the proportion of weight lost as lean tissue rather than fat.

Claims that amylin-based medicines preserve muscle better than GLP-1 drugs alone remain insufficiently established. Dedicated human body-composition studies and direct comparisons will be needed to settle that question.

There is also the issue of durability. Early studies can show rapid weight reduction over several months. Longer trials must establish how well participants tolerate dose escalation, whether weight loss continues, and what happens when treatment is interrupted or stopped.

What Zenagamtide Still Has to Prove

The next decisive tests are clear. AMAZE 7 should show how weekly injectable zenagamtide performs against semaglutide over 84 weeks. AMAZE 9 will extend the evidence for the oral formulation in obesity. Other studies in the development program will address additional metabolic conditions and longer-term outcomes.

The existing human results justify those trials. Estimated weight loss above 20% in early obesity cohorts is a substantial signal, and the diabetes Phase 2 findings show that the molecule also has meaningful glucose-lowering activity. But high rates of gastrointestinal adverse events and the limitations of small early studies prevent confident predictions about long-term performance.

Novo also needs to establish where zenagamtide fits commercially. A drug that improves on semaglutide but falls short of tirzepatide could still have a role, depending on tolerability, dosing, availability and patient response. A drug that consistently outperforms existing options would have a much larger opportunity.

The early data do not yet distinguish between those possibilities.

Zenagamtide has a new name and an established comparator. The long-term clinical evidence is still being collected.

For Novo Nordisk, the issue is not whether amycretin can make people lose weight. The early studies have already demonstrated that it can. The harder question is whether one engineered peptide can deliver enough additional benefit to compete with the drugs that now define the obesity market.

AMAZE 7 is designed to begin answering that question. Its 2028 completion target is a reminder that promising peptide chemistry and a proven treatment are separated by years of clinical testing.

Sources

  1. ClinicalTrials.gov — AMAZE 7: Zenagamtide Compared With Semaglutide (NCT07668414), registry updated September 2026.
  2. Novo Nordisk — Financial Report for the First Nine Months of 2026, November 4, 2026.
  3. Dahl K, et al. — Amycretin, a Novel Unimolecular GLP-1 and Amylin Receptor Agonist Administered Subcutaneously: Phase 1b/2a Study, The Lancet, 2025.
  4. Mora P, et al. — Efficacy and Safety of Once-Weekly Subcutaneous Zenagamtide in Type 2 Diabetes: Phase 2 Trial, The Lancet, August 2026.
  5. Mora P, et al. — Efficacy and Safety of Once-Daily Oral Zenagamtide in Type 2 Diabetes: Phase 2 Trial, The Lancet, August 2026.
  6. Novo Nordisk — Zenagamtide Phase 2 Diabetes Results Presented at ADA 2026, June 2026.
  7. Novo Nordisk — REDEFINE 4: CagriSema Compared With Tirzepatide, February 23, 2026.
  8. Novo Nordisk Clinical Trials — AMAZE 9: Oral Zenagamtide Phase 3 Study, 2026.
  9. Fierce Biotech — Novo’s Injectable Amycretin and Early Weight-Loss Results, June 23, 2025.

Read more

Local News